The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 years or older, according to a press release from manufacturer Insmed.

NCFB affects approximately 500,000 individuals in the US and millions globally, according to the press release. The condition is distinct from other respiratory infections, in that it involves widening of the airways rather than narrowing.

Exacerbations involving coughing, increased mucus, and shortness of breath are common and disruptive, but targeted treatments have been lacking, according to the company. Brensocatib, marketed as Brinsupri, is a first-in-class inhibitor of DPP-1, designed to prevent the activation of neutrophils that drive the chroni

See Full Page